Base to Base biotech podcast 22: A new treatment for dry AMD and tackling peanut allergies

This week, we talk about new treatments for wet dry age-related macular degeneration (AMD) with Judith Greciet, CEO of PulseSight Therapeutics, and there’s a conversation with Maite Agüeros, CEO and co-founder of InnoUp Farma about, among other things, peanut allergies.Interview times: 03:24 PulseSight 20:43 InnoUpTackling dry AMDPulseSight Therapeutics SAS, an ophthalmology biotech company developing non-viral vectorised therapies with minimally-invasive delivery technology, recently announced the first patient has been successfully dosed in its phase I clinical trial (PST-611-CT1) aiming to assess safety and tolerability of its lead programme, PST-611, in humans.PST-611 is a first-in-class non-viral vectorized therapy for the treatment of dry age-related macular degeneration (AMD)/geographic atrophy (GA), expressing human transferrin, a highly potent iron regulator, playing a central role in restoring normal iron homeostasis.AMD is the leading cause of central vision loss in the elderly, affecting 200m people worldwide. AMD's pathogenesis is complex, and the disease still represents a high unmet medical need. Dry AMD involves the dysregulation of iron homeostasis, leading to an excess of free iron causing highly toxic effects such as inflammation, oxidative stress, and ultimately retinal cell death (ferroptosis).PST-611-CT1 is a first-in-human single ascending dose study that aims to establish, in six to a maximum of 12 dry AMD/GA patients, the safety profile of the drug and validate the maximal tolerated dose in view of the following phase IIa proof-of-concept trial. Preliminary results are anticipated early 2026, subject to patient recruitment.Our conversation is with Judith Greciet, CEO of PulseSight Therapeutics.New ways to treat peanut allergiesInnoUp is a clinical stage company specialising in nanotechnology innovations and developing oral drug delivery solutions. It has developed a Nanoparticle Platform that is protected by international patents.InnoUp has two programmes currently in the clinical stage: an oral peanut allergy vaccine (INP20) and an oral Paclitaxel to treat breast cancer (INP12).We have a conversation with Maite Agüeros, CEO and co-founder of InnoUp. To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email [email protected]

There are no comments yet.

Please log in to write the first comment.